Article
Oral immunotherapy with omalizumab reverses the Th2 cell-like programme of regulatory T cells and restores their function.
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology - 1 Jul 2018
Abdel-Gadir A, Schneider L, Casini A, Charbonnier L-M, Little S V, Harrington T, Umetsu D T, Rachid R, Chatila T A
Abstract excerpt
BACKGROUND: Oral immunotherapy (OIT) successfully desensitizes patients with food allergies, but the immune mechanisms mediating its efficacy remain obscure. OBJECTIVES: We tested the hypothesis that allergen-specific regulatory T (Treg) cell function is impaired in food allergy and is restored by anti-IgE antibody (omalizumab)-supplemented OIT. METHODS: Peanut-specific T effector (Teff) and Treg cell...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.